A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy – CLINICAL CANCER RESEARCH

Weiss, SA; Sznol, M; Shaheen, M; Berciano-Guerrero, MA; Couselo, EM; Rodríguez-Abreu, D; Boni, V; Schuchter, LM; Gonzalez-Cao, M; Arance, A; Wei, W; Ganti, AK; Hauke, RJ; Berrocal, A; Iannotti, NO; Hsu, FJ; Kluger, HM – 2024 –...

Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma – CLINICAL CANCER RESEARCH

Flechon, A; Morales-Barrera, R; Powles, T; Alva, A; Özgüroglu, M; Csöszi, T; Loriot, Y; Rodriguez-Vida, A; Géczi, L; Cheng, SY; Fradet, Y; Oudard, S; Vulsteke, C; Gunduz, S; Mamtani, R; Yu, EY; Pino, AM; Anido, U; Sendur, MAN; Gravis, G; Révész, J; Kostorov, V;...

Dynamic nature of BRAF or KRAS p.G12C mutations in second-line therapy for advanced colorectal cancer patients: do early and late effects exist? – BRITISH JOURNAL OF CANCER

Contreras-Toledo, D; Jiménez-Fonseca, P; López, CL; Montes, AF; Muñoz, AML; Rivera, FV; Alonso, V; Alcaide, J; Salvà, F; Rúa, MC; Guillot, M; Carnicero, AM; Mate, RJ; García, SC; Martínez, EA; Astorga, BG; Fernandez-Diaz, AB; Villaroel, PG; Manrique, ACV; Sosa, MM;...